US2016222026A1PendingUtilityA1
Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors
Est. expiryOct 28, 2026(~0.3 yrs left)· nominal 20-yr term from priority
Inventors:Robert DezielSilvana LeitPatrick BeaulieuYves ChantignyJohn MancusoPierre TessierGideon ShapiroRichard ChesworthDavid Smil
A61P 43/00A61P 25/28A61P 25/00A61P 25/14A61P 21/00C07D 209/94C07D 223/24C07H 13/10C07D 285/36C07D 239/28C07D 267/20C07D 267/18C07D 267/14C07D 209/52C07D 487/08C07D 209/02C07D 279/22C07D 498/04C07D 471/14C07D 495/04C07D 281/16C07C 259/10C07D 313/12C07D 243/24C07D 209/08C07D 223/20C07D 487/14C07D 223/28C07D 223/16C07D 295/155C07D 401/14C07D 403/14C07D 413/06C07D 265/38C07D 221/12C07D 239/34C07D 413/12C07D 403/04C07C 259/06C07D 491/08C07D 225/08C07D 487/04C07D 223/22C07D 279/26C07D 291/08C07D 239/42C07D 471/08C07D 513/04C07D 471/04C07D 243/38C07D 223/26A61K 31/55
50
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound represented by Formula (I):
and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic mixtures, diastereomers and enantiomers thereof, wherein
Z is selected from the group consisting of —N(R 1 )OR 2 and H;
L is selected from the group consisting of a covalent bond and —N(OR 2 )—;
wherein, when L is —N(OR 2 )—, Z is H; and
wherein, when Z is H, L is —N(OR 2 )—;
J is selected from the group consisting of a covalent bond, ═CH—, —C 1 -C 8 alkyl-, —C 0 -C 3 alkyl-C 1 -C 8 heteroalkyl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-C 2 -C 8 alkenyl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-C 2 -C 8 alkynyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 heteroalkyl-, —C 0 -C 3 alkyl-C 1 -C 6 heteroalkyl-aryl-C 0 -C 6 alkyl-, —C 0 -C 3 alkyl-C 1 -C 6 heteroalkyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-cycloalkyl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 6 alkyl-, —C 4 -C 6 heterocyclyl-aryl-C 0 -C 6 alkyl-, —C 4 -C 6 heterocyclyl-aryl-C 0 -C 6 heteroalkyl-, —C 0 -C 6 alkyl-C 4 -C 6 heterocyclyl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkylheteroaryl-C 0 -C 6 heteroalkyl-, —C 4 -C 6 heterocyclyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 alkynyl-, —C 0 -C 6 alkyl-heteroaryl-C 2 -C 6 alkynyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 alkynyl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-heteroaryl-C 2 -C 6 alkenyl-, —C 0 -C 3 alkyl-C 2 -C 6 alkenyl-aryl-C 0 -C 6 alkyl-, —C 0 -C 3 alkyl-C 2 -C 6 alkenyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 3 alkyl-C 2 -C 6 alkynyl-aryl-C 0 -C 6 alkyl-, —C 0 -C 3 alkyl-C 2 -C 6 alkynyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkylaryl-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkylaryl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 3 alkyl-heteroaryl-heteroaryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-heteroaryl-aryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-aryl-heteroaryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-aryl-aryl-C 0 -C 3 alkyl-, and —C 0 -C 6 alkyl-C 3 -C 6 cycloalkyl-C 0 -C 6 alkyl-, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl moiety is optionally substituted, and wherein when J is ═CH—, Q is a covalent bond and B is attached through a carbon sp 2 to J;
Q is selected from the group consisting of an optionally substituted:
or where possible, an (R,R) or (S,S) enantiomer or a mixture of enantiomers thereof,
wherein G and G 1 are independently selected from carbon and N; the variables I, m, n, o and p denote numbers that are each independently selected from 0, 1, 2 or 3 provided that the sum total of 1, m, n, o and p is 4, 5, 6 or 7, such that the group represented by Q comprises a 6, 7, 8 or 9 membered bridged or fused heterocyclyl, respectively, and further provided that when G and G 1 are both N then the sum total of l and o is not zero, and the sum total of m and p is not zero, and wherein n is an integer ranging from 0 to 3;
U is selected from the group consisting of —C 0 -C 8 alkyl-C(O)—C 0 -C 3 alkyl-, —C 1 -C 8 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-O—C(O)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—C(S)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-O—C(S)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—S(O) 2 —C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-heterocyclyl-C 0 -C 3 alkyl-, a covalent bond and —O—C 2 -C 4 alkyl-; and
U 1 is selected from the group consisting of H, —C(R 1 )(R 2 )—, —C 0 -C 8 alkyl-C(O)—C 0 -C 3 alkyl-, —C 1 -C 8 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-, —C(R 1 )(R 2 )—N(R 3 )—C(O)—C 0 -C 3 alkyl-, —C(R 1 )(R 2 )—C(O)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-O—C(O)—C 0 -C 3 alkyl-, —C(R 1 )(R 2 )—O—C(O)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—C(S)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-O—C(S)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—S(O) 2 —C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-heterocyclyl-C 0 -C 3 alkyl-, a covalent bond, (R 3 )(R 3a )N—C 2 -C 4 alkyl-, —O—C 2 -C 4 alkyl-, and R 3 —O—C 2 -C 4 alkyl-;
or
Q is selected from the group consisting of a covalent bond, —C 1 -C 8 alkyl-, —C 1 -C 8 alkyl-, —C 1 -C 8 heterocyclyl-, ═N—O—, —C 0 -C 6 alkyl-N(R 3 )—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-O—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-S(O) 0-2 —C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-C(O)—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-O—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-cycloalkyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-N(R 3 )—C(O)-cycloalkyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-N(R 3 )-cycloalkyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-S(O) 0-2 —N(R 3 )-cycloalkyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-N(R 3 )—C(O)—N(R 3 )-cycloalkyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-O—C(O)—O-cycloalkyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-N(R 3 )—C(O)—O-cycloalkyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-(CR 3 ═CR 3 ) 1-2 —C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-(C≡C) 1-2 —C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-N(R 3 )—C(O)-alkenyl-C 0 -C 4 alkyl-, —C 0 -C 6 alkyl-C(O)—N(R 3 )—C 0 -C 4 alkyl-, —C 0 -C 6 alkyl-SO 2 —N(R 3 )—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-N(R 3 )—SO 2 —C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-N(R 3 )—S(O) 2 —N(R 3 )—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-S—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-S(O)—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-S(O) 2 —C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-N(R 3 )—C(O)—N(R 3 )—C 0 -C 3 alkyl-, ═N—O—C 0 -C 3 alkyl-, -heterocyclyl-C 0 -C 3 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —SO 2 —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C(O)—C 0 -C 6 alkyl-bridged heterocyclyl-C 0 -C 3 alkyl-, —N(R 3 )—C(O)—C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —O—C(O)—C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —N(R 3 )—C(S)—C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —O—C(S)—C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —N(R 3 )—S(O) 2 —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-SO 2 —N(R 3 )—, —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-C(O)—N(R 3 )— and —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-C(O)—O—, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted; wherein
is selected from the group consisting of b-1a to b-1k and b-1 to b-125, and wherein when Q is attached to
via ═N—O—, or ═N—O—C 0-3 alkyl, it is attached through carbon Sola-Penna et al. 2 in
and wherein each alkyl, heteroalkyl, cycloalkyl, heterocyclyl and alkenyl moiety is optionally substituted; and wherein when Q is a covalent bond and J is attached to
via ═CH—, then it is attached through carbon sp 2 in
or
when
is selected from the group consisting of b-1 to b-121 and is attached to Q via a N in
then Q is selected from the group consisting of a covalent bond, —C(O)—C 1 -C 3 alkyl-O—, —C 1 -C 8 alkyl-, —C 2 -C 6 alkyl-N(R 3 )—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-C(O)—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-O—C 0 -C 3 alkyl-, —C 1 -C 6 alkyl-(CR 3 ═CR 3 ) 1-2 —C 0 -C 6 alkyl-, —C 2 -C 6 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl, —C 2 -C 6 alkyl-N(R 3 )—C(O)-alkenyl-C 0 -C 3 alkyl, —C 0 -C 6 alkyl-C(O)—N(R 3 )—C 0 -C 4 alkyl-, —C(O)—O—C 0 -C 4 alkyl, —C 0 -C 6 alkyl-S(O) 2 —N(R 3 )—C 0 -C 3 alkyl, —C 2 -C 6 alkyl-N(R 3 )—S(O) 2 —C 0 -C 3 alkyl, —C 2 -C 3 alkyl-N(R 3 )—S(O) 2 —N(R 3 )—C 0 -C 3 alkyl-, —C 2 -C 6 alkyl-S—C 0 -C 3 alkyl, —C 2 -C 6 alkyl-S(O)—C 0 -C 3 alkyl, —C 0 -C 6 alkyl-S(O) 2 —C 0 -C 3 alkyl, —C 2 -C 6 alkyl-N(R 3 )—C(O)—N(R 3 )—C 0 -C 3 alkyl, —C 2 -C 3 alkyl-C═N—O—C 0 -C 3 alkyl, —SO 2 —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C(O)—C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 2 -C 4 alkyl-N(R 3 )—C(O)—C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 2 -C 4 alkyl-O—C(O)—C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 2 -C 4 alkyl-N(R 3 )—C(S)—C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 2 -C 4 alkyl-O—C(S)—C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 2 -C 4 alkyl-N(R 3 )—S(O) 2 —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-S(O 2 )—N(R 3 )—, —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-C(O)—N(R 3 )— and —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-C(O)—O—, wherein each alkyl, heterocyclyl and alkenyl moiety is optionally substituted, and wherein the heterocyclyl moiety is optionally bridged with —(CH 2 ) 0-3 —;
R 1 and R 2 are independently selected from the group consisting of —H, C 1 -C 6 alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protecting group;
each R 3 is independently selected from the group consisting of —H, alkyl, C 0 -C 3 alkyl-heterocyclyl, C 1 -C 3 alkyl-C 2 -C 6 alkenyl, C 1 -C 3 alkyl-C 2 -C 3 alkynyl, —C 2 -C 4 alkyl-OR 1 , —C 2 -C 4 alkyl-NR 3b R 3c , —C 2 -C 4 alkyl-NR 1 R 2 , heteroalkyl, C 0 -C 6 alkylheteroaryl, C(O)CF 3 , —C(O)—NH 2 , —C(O)—NR 3b R 3c , —C(O)—NR 1 R 2 , —C(O)—OR 1 , —S(O) 2 —NR 1 R 2 , —S(O) 2 —R 1 , —C(O)—R 1 , —C 3 -C 6 cycloalkyl, —C 0 -C 3 alkyl-C 3 -C 7 cycloalkyl, —C 1 -C 6 alkylaryl, aryl, C 0 -C 3 alkyl-heteroaryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted with from one to three independently selected substituents;
each R 3a is independently selected from the group consisting of —H, alkyl, heterocyclyl, C 2 -C 6 alkenyl, C 2 -C 3 alkynyl, C 2 -C 4 alkyl-OR 1 , heteroalkyl, heteroaryl, C 0 -C 6 alkylheteroaryl, C(O)CF 3 , —C(O)—NH 2 , —C 3 -C 6 cycloalkyl, -alkyl-C 3 -C 6 cycloalkyl, —C 1 -C 6 alkylaryl, aryl, alkylheteroaryl and heteroaryl, covalent bond, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted;
wherein R 3 and R 3a , together with the atom to which they are attached, optionally form a heterocyclic ring, wherein the heterocyclyl moiety is optionally substituted;
wherein R 3b and R 3c , together with the atom to which they are attached, optionally form a heterocyclic ring, wherein the heterocyclyl moiety is optionally substituted; provided that
is absent when Q is structure (a-1), (a-2), (a-3), (a-20) or when U 1 is H, N(R 3 )(R 3a )—C 2 -C 4 alkyl- or R 3 —O—C 2 -C 4 alkyl-;
is selected from the group consisting of hydrogen, aryl, aryl-alkyl-, heteroaryl, heteroaryl-alkyl-, heterocyclyl, cycloalkyl, heterocyclyl-alkyl, cycloalkyl-alkyl, C 1 -C 10 alkyl, (aryl) 2 -CH—C 0 -C 6 alkyl-, (aryl)(heteroaryl)CH—C 0 -C 6 alkyl- and (heteroaryl) 2 CH—C 0 -C 6 alkyl-, each of which is optionally substituted; or
is a radical selected from the group consisting of
wherein
are independently selected from phenyl, a 5- or 6-membered heteroaryl and a heterocyclyl, wherein each of which is optionally substituted with one to three independently selected substituents;
provided that when
is selected from the group consisting of hydrogen, aryl, aryl-alkyl-, heteroaryl, heteroaryl-alkyl-, heterocyclyl, cycloalkyl, heterocyclyl-alkyl, cycloalkyl-alkyl, C 1 -C 10 alkyl, (aryl) 2 -CH—C 0 -C 6 alkyl-, (aryl)(heteroaryl)CH—C 0 -C 6 alkyl- and (heteroaryl) 2 CH—C 0 -C 6 alkyl-, each of which is optionally substituted, then Q is selected from the group consisting of a-3, a-4, a-5, a-6, a-7, a-8, a-9, a-10, a-11, a-12, a-13 and a-14,
wherein
each A is independently selected from the group consisting of N, —N-oxide, —CH═ and —C(R 4 )═, wherein no more than two A per 5 or 6 membered ring are N in a
group, and wherein no more than one A is —N-oxide;
the group M 1 -M 2 is selected from the group consisting of a covalent bond, —N(R 3 )CH 2 —, —CH 2 N(R 3 )—, —S(O) 0-2 —CH 2 —, —CH 2 S(O) 0-2 -, —O—CH 2 —, —CH 2 —O—, —C(O)N(R 3 )—, —C(O)—O—, —C(O)—CH 2 —, —CH(OH)—CH 2 —, —CH(F)—CH 2 —, —CH 2 —C(O)—, —CH 2 —CH(OH)—, —CH 2 —CH(F)—, —N(R 3 )—C(O)—, —SO 2 N(R 3 )—, —N(R 3 )SO 2 —, —CH(R 4 )CH 2 —, —CH 2 CH(R 4 )—, —N═C(R 4 )—, —C(R 4 )═N—, —CH 2 —CH 2 —, —CH═CH—, —CH(R 3 )—CH(R 3 )—, —C(R 3 )═C(R 3 )—, —C(R 4 )═C(R 4 )—, —CF═CH—, —CH═CF—,
—CH 2 —, —C(R 3 )(R 3a )—, —S(O) 0-2 -, —N(R 3 )—, or absent;
M 3 is selected from the group consisting of
or M 3 is
wherein Q is attached to
via ═N—O—, or ═N—O—C 0-3 alkyl, or J is attached to
via ═CH—,
wherein * represents the point of attachment to Q;
M 4 is selected from the group consisting of
and covalent bond;
wherein, when M 1 -M 2 is a covalent bond, M 4 is selected from the group consisting of
the groups D 1 -D 2 and D 1a -D 2a are selected from the group consisting of
wherein, * represents the point of attachment to Q;
D 3 is selected from the group consisting of a covalent bond,
wherein the
are optionally substituted;
D 4 is selected from the group consisting of
wherein the
is optionally substituted;
the group E 1 -E 2 is selected from the group consisting of
wherein * represents the point of attachment to Q; and
E 3 is selected from the group consisting of —C(O)—, —C(S)—, —CH 2 —, —C(OH) 2 — and —C═N(R 3 )—; and
R 4 is independently selected from the group consisting of —H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkyl-R 3 , —C 0 -C 6 alkyl-OR 3 , —C 0 -C 6 alkyl-OR 1 , —C 0 -C 6 alkyl-C(O)—OR 3 , —C 0 -C 6 alkyl-C(O)NR 3 R 3a , —CH═CH—C(O)—OR 3 , —CH═CH—C(O)—N(R 3 )(R 3a ), —N(R 3 )—C(O)—CF 3 , —N(R 3 )—C 2 -C 6 alkyl-N(R 3 )(R 3a ), —C 0 -C 6 alkyl-N(R 3 )(R 3a ), —N(R 3 )—C(O)—C 1 -C 6 alkyl-R 3 , —N(R 3 )—S(O) 2 —C 1 -C 6 alkyl-R 3 , —S(O) 2 —N(R 3 )R 3a , —O—C 2 -C 6 alkyl-N(R 3 )(R 3a ), —O—C 2 -C 6 alkyl-OR 1 , —S—R 3 , —S(O)—C 1 -C 6 alkyl-R 3 , —S(O) 2 —C 1 -C 6 alkyl-R 3 , C 3 -C 6 cycloalkyl, heterocyclyl, C 4 -C 7 heterocyclyl-R 3 , —O—C 2 -C 4 alkyl-heterocyclyl, —O-heterocyclyl-C(O)—OR 3 , —O—C 0 -C 4 alkyl-aryl, —O—C 0 -C 4 alkyl-heteroaryl, —O—C(O)—NR 3 —C 0 -C 4 alkyl-aryl, —O—C(O)—NR 3 —C 0 -C 4 alkyl-heteroaryl, —O—C 0 -C 4 alkyl-heterocyclylaryl, —O—C 0 -C 4 alkyl-heterocyclyl-heteroaryl, —N(R 3 )—C 2 -C 4 alkyl-heterocyclyl, —N(R 3 )C(O)N(R 3 )—C 0 -C 4 alkyl-heterocyclyl-R 3 , —C 0 -C 4 alkyl-OC(O)—R 3 , —C 0 -C 4 alkyl-N(R 3 )C(O)—O—R 3 , —C 0 -C 4 alkyl-heterocyclyl-C(O)—O—R 3 , —N(R 3 )—C 2 -C 4 alkyl-heterocyclyl, F, Cl, Br, I, NO 2 , —CF 3 , —OCF 3 , —OCHF 2 , —SCF 3 , —SF 5 , —SO 3 H, —CN, —C 1 -C 6 alkylaryl, aryl, heteroaryl, cycloalkyl, —C 1 -C 6 alkylheteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moeity of the aformentioned R 4 is optionally substituted;
or
is selected from the group consisting of structures b-1a to b-1k and (b-1) to (b-125) and Q-J-L taken together is selected from the group consisting of —C 3 -C 8 alkyl-, —C(O)—C 3 -C 8 alkyl-, —C 0 -C 3 alkyl-O—C 3 -C 8 alkyl-, —C 0 -C 3 alkyl-C 1 -C 4 alkenyl-C 0 -C 3 alkyl-, ═N—O—C 1 -C 8 alkyl-, ═N—O—C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, ═N—O—C 0 -C 3 alkyl-aryl-C 0 -C 3 alkenyl-, ═N—O—C 0 -C 3 alkyl-aryl-C 0 -C 3 alkynyl-, ═N—O—C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl-, ═N—O—C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkenyl-, ═N—O—C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkynyl-, —C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-aryl-C 2 -C 4 alkenyl-, —C 0 -C 3 alkyl-aryl-C 2 -C 4 alkynyl-, —C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-heteroaryl-C 1 -C 3 alkenyl-, —C 0 -C 3 alkyl-heteroaryl-C 1 -C 3 alkynyl-, —C 0 -C 3 alkyl-N(R 3 )—C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-N(R 3 )—C 0 -C 3 alkyl-aryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-N(R 3 )—C 0 -C 3 alkyl-aryl-C 2 -C3alkynyl-, —C 0 -C 3 alkyl-N(R 3 )—C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-N(R 3 )—C 0 -C 3 alkyl-heteroaryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-N(R 3 )—C 0 -C 3 alkyl-heteroaryl-C 2 -C 3 alkynyl-, —C 0 -C 3 alkyl-C(O)—N(R 3 )—C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-C(O)—N(R 3 )—C 0 -C 3 alkyl-aryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-aryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-C(O)—N(R 3 )—C 0 -C 3 alkyl-aryl-C 2 -C 3 alkynyl-, —C 0 -C 3 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-aryl-C 2 -C 3 alkynyl-, —C 0 -C 3 alkyl-C(O)—N(R 3 )—C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-C(O)—N(R 3 )—C 0 -C 3 alkyl-heteroaryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-heteroaryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-C(O)—N(R 3 )—C 0 -C 3 alkyl-heteroaryl-C 2 -C 3 alkynyl-, —C 0 -C 3 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-heteroaryl-C 2 -C 3 alkynyl-, —C 0 -C 3 alkyl-heterocyclyl-C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-C(O)-heterocyclyl-C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-N(R 3 )—C(O)-heterocyclyl-C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-O—C(O)-heterocyclyl-C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-heterocyclyl-C 0 -C 3 alkyl-aryl-C 2 -C 4 alkenyl, —C 0 -C 3 alkyl-C(O)-heterocyclyl-C 0 -C 3 alkyl-aryl-C 2 -C 4 alkenyl, —C 0 -C 3 alkyl-N(R 3 )—C(O)-heterocyclyl-C 0 -C 3 alkyl-aryl-C 2 -C 4 alkenyl, —C 0 -C 3 alkyl-O—C(O)-heterocyclyl-C 0 -C 3 alkyl-aryl-C 2 -C 4 alkenyl, —C 0 -C 3 alkyl-heterocyclyl-C 0 -C 3 alkyl-aryl-C 2 -C 4 alkynyl, —C 0 -C 3 alkyl-C(O)-heterocyclyl-C 0 -C 3 alkyl-aryl-C 2 -C 4 alkynyl, —C 0 -C 3 alkyl-N(R 3 )—C(O)-heterocyclyl-C 0 -C 3 alkyl-aryl-C 2 -C 4 alkynyl, —C 0 -C 3 alkyl-O—C(O)-heterocyclyl-C 0 -C 3 alkyl-aryl-C 2 -C 4 alkynyl, —C 0 -C 3 alkyl-heterocyclyl-C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl, —C 0 -C 3 alkyl-C(O)-heterocyclyl-C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl, —C 0 -C 3 alkyl-N(R 3 )—C(O)-heterocyclyl-C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl, —C 0 -C 3 alkyl-O—C(O)-heterocyclyl-C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl, —C 0 -C 3 alkyl-heterocyclyl-C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-C(O)-heterocyclyl-C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-N(R 3 )—C(O)-heterocyclyl-C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-O—C(O)-heterocyclyl-C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkenyl-, —C 0 -C 3 alkyl-heterocyclyl-C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkynyl-, —C 0 -C 3 alkyl-C(O)-heterocyclyl-C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkynyl-, —C 0 -C 3 alkyl-N(R 3 )—C(O)-heterocyclyl-C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkynyl-, —C 0 -C 3 alkyl-O—C(O)-heterocyclyl-C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkynyl-, —C 2 -C 4 alkyl-O—C 0 -C 3 alkyl-aryl-, —C 2 -C 4 alkyl-O—C 0 -C 3 alkyl-aryl-C 0 -C 3 alkyl-, —C 2 -C 4 alkyl-O—C 0 -C 3 alkyl-aryl-C 2 -C 4 alkenyl, —C2-C4alkyl-O—C 0 -C 3 alkyl-aryl-C 2 -C 4 alkynyl, —C 2 -C 4 alkyl-O—C 0 -C 3 alkyl-heteroaryl-C 0 -C 3 alkyl, —C 2 -C 4 alkyl-O—C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkenyl-, —C 2 -C 4 alkyl-O—C 1 -C 3 alkyl-heteroaryl-C 2 -C 3 alkynyl-, —C 0 -C 6 alkyl-U-bridged heterocyclyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-U-bridged heterocyclyl-N(R 3 )-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-U—N(R 3 )-bridged heterocyclyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-U-bridged heterocyclyl-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-U-bridged heterocyclyl-N(R 3 )-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-U—N(R 3 )-bridged heterocyclyl-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-U-bridged heterocyclyl-aryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-U-bridged heterocyclyl-N(R 3 )-aryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-U—N(R 3 )-bridged heterocyclyl-aryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-U-bridged heterocyclyl-heteroaryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-U-bridged heterocyclyl-N(R 3 )-heteroaryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-U—N(R 3 )-bridged heterocyclyl-heteroaryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-bridged heterocyclyl-U-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-N(R 3 )-bridged heterocyclyl-U-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-bridged heterocyclyl-N(R 3 )—U-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-bridged heterocyclyl-U-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-N(R 3 )-bridged heterocyclyl-U-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-bridged heterocyclyl-N(R 3 )—U-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-bridged heterocyclyl-U-aryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-N(R 3 )-bridged heterocyclyl-U-aryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-bridged heterocyclyl-N(R 3 )—U-aryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-bridged heterocyclyl-U-heteroaryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-N(R 3 )-bridged heterocyclyl-U-heteroaryl-C 2 -C 6 alkenyl-, and —C 0 -C 6 alkyl-bridged heterocyclyl-N(R 3 )—U-heteroaryl-C 2 -C 6 alkenyl-,
wherein each alkyl, alkenyl, aryl, alkynyl, heteroaryl and heterocyclyl moiety is optionally substituted; and wherein the bridge is methylene or propylene;
provided that Formula (I) excludes those compounds wherein
-Q-J-L-C(O)Z is optionally substituted —C 1 -C 13 alkyl-N(R 3 )—C 0 -C 6 alkyl-aryl-C 2 alkenyl-C(O)NHOH; and
is selected from the group consisting of aromatic polycycles, non-aromatic polycycles, mixed aryl and non-arylpolycycles, polyheteroaryl, non-aromatic polyheterocycles, and mixed aryl and non-aryl polyheterocycles, each of which is optionally substituted;
and
provided that Formula (I) excludes compounds of Formula (A)
wherein R 906 is selected from the group consisting of aryl and heteroaryl;
T 906 is selected from the group consisting of —O 0-6 alkyl-S(O) 2 —O 0-6 alkyl-, —C 0-6 alkyl-C(O)—C 0-6 alkyl- and C 1-3 alkyl, wherein T 906 is substituted at the carbon atom attached to R 906 with a moiety selected from the group consisting of; aryl, heteroaryl, cycloalkyl and heterocycle;
A 906 is an optionally substituted unbridged heterocycle;
Q 906 is a bond;
Het is an optionally substituted 5-membered aryl ring;
L 906 is a bond or —C 1-4 alkyl-; and
R 906a is —N(R 906b )OH, wherein R 906b is selected from the group consisting of H, optionally substituted alkyl and optionally substituted aryl;
and
provided that Formula (I) excludes those compounds wherein
-Q-J-L-C(O)Z is optionally substituted —C 0 -C 4 alkyl-X—C 1 -C 4 alkyl-phenyl-C 2 alkenyl-C(O)NHOH;
is a 5- or 6-membered aromatic heterocyclic group condensed with a carbon ring or other heterocyclic ring, which
is substituted with 1 to 4 substituents selected from phenyl, another 5- or 6-membered aromatic heterocyclic group and a heterocyclic group, said heterocyclic group being optionally substituted with C 1-4 alkyl, a benzyl group or a pyridylmethyl group; and
X is a moiety having a structure selected from the group consisting of —C(O)N(R A1 )—, —O—C(O)—N(R A1 )—, —SO 2 —, —N(R A2 )SO 2 —, wherein R A1 and R A2 are independently —H or optionally substituted C 1 -C 4 alkyl;
and
provided that Formula (I) excludes compounds wherein B-Q- is
and
-J-L- is
wherein R is directly attached or attached through a linker, and is selected from the group consisting of substituted or unsubstituted aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, 9-purine-6-amine, thiazoleamino group, hydroxyl, branched or unbranched alkyl, alkenyl, alkyoxy, aryloxy, arylalkyloxy and pyridine group, wherein the linker is selected from the group consisting of an amide moiety, —O—, —S—, —NH— and —CH 2 —; and
provided that Formula (I) excludes compounds of Formula (B)
wherein
R B is H or phenyl;
A B is a bi- or tricyclic residue optionally partially or totally unsaturated, and which optionally contains one or more heteroatoms selected from the group consisting of N, S and O, and optionally substituted by hydroxy, alkanoyloxy, primary, secondary or tertiary amino, aminoC 1 -C 4 alkyl, mono- or di(C 1 -C 4 )alkyl-aminoC 1 -C 4 alkyl, halogen, C 1 -C 4 alkyl and tri(C 1 -C 4 )alkylammoniumC 1 -C 4 alkyl;
is a chain of 1 to 5 carbon atoms optionally containing a double bond or an NR group, wherein R is H or C 1 -C 4 alkyl;
X B is absent, an oxygen atom or an NR group, wherein R is H or C 1 -C 4 alkyl; and
B B is a phenylene or cyclohexylene ring;
and
provided that Formula (I) excludes compounds of Formula (D)
wherein
A D is selected from the group consisting of a 4- to 10-membered aromatic or non-aromatic heterocyclyl;
X D is C═O or S(O) 2 ;
R D1 is H or C 1 -C 6 alkyl;
R D2 is independently selected from the group consisting of oxo, (C═O)—NH 2 , C 1 -C 6 alkyl-aryl and heterocyclyl, when A D is a non-aromatic heterocycle, wherein said alkyl, and aryl moieties are optionally substituted with one to three R b ; or
R D2 is independently selected from the group consisting of OH, NO 2 , (C═O) 0-1 —O 0-1 —C 1 -C 6 alkyl, CN, (C═O) 0-1 —O 0-1 —C 3 -C 10 cycloakyl, halogen, (C═O) 0-1 —N(R a ) 2 , CF 3 , NH—S(O) 0-2 —R a , (C═O) 0-1 —O 0-1 -heterocyclyl, (C═O) 0-1 —O 0-1 -aryl, S(O) 0-2 —R a , NH(C═O)R a , C 1 -C 6 alkyl-aryl and heterocyclyl, when A D is an aromatic heterocyclyl, wherein said alkyl, cycloalkyl, aryl and heterocyclyl are optionally substituted with one to three R b ;
R a is independently H or C 1 -C 6 alkyl; and
R b is independently selected from the group consisting of oxo, NO 2 , N(R a ) 2 , OH, CN, halogen, CF 3 and C 1 -C 6 alkyl;
and
provided that Formula (I) excludes compounds of Formula (E)
wherein
A E is selected from the group consisting of —CH 2 —O—, —CH 2 —S—, —CH 2 —CH 2 — and —NH—CO—;
X E is selected from the group consisting of —N(R E3 )—, ═C(O) and —CH(OH)—;
Y E is selected from the group consisting of O, S and —N(R E4 )—;
Z E is selected from the group consisting of a straight chain C4-C8alkylene, wherein one CH 2 group may be replaced by an oxygen or a sulfur atom, or wherein 2 carbon atoms form a C═C double bond, and which is either unsubstituted or substituted by one or two substituents selected from C 1 -C 4 alkyl and halogen;
R E1 and R E2 are independently selected from the group consisting of H, halogen, C 1 -C 4 alkyl, trifluoromethyl, hydroxy, C 1 -C 4 alkoxy, benzyloxy, C 1 -C 3 alkylenedioxy, nitro, amino, C 1 -C 4 alkylamino, di[(C 1 -C 4 )alkyl]-amino, and C 1 -C 4 alkanoylamino; and
R E3 and R E4 are independently selected from H and C 1 -C 4 alkyl; and
provided that Formula (I) excludes compounds of Formula (F)
A F -Q 1F -J F -Q 2F -C(O)—NH—OH (F)
wherein
A F is a C 5 -C 20 aryl group or a 5-20 membered heteroaryl group, each having one ring or two or more fused rings, wherein at least one ring is aromatic, said ary and heteroaryl groups being optionally substituted;
Q 1F is a linker group having a backbone length of at least 2 carbon atoms, the linker being optionally substituted;
J F is —N(R F )—C(O)— or —C(O)—N(R F )—;
Q 2F is selected from the group consisting of C 1 -C 10 alkyl, C 5 -C 20 aryl, 5 to 20 membered heteroaryl, C 5 -C 20 aryl-C 1 -C 10 alkyl, 5 to 20 membered heteroaryl-C 1 -C 10 alkyl, C 1 -C 10 alkyl-C 5 -C 20 aryl and C 1 -C 10 alkyl-5 to 20 membered heteroaryl, each of which is optionally substituted; and
R F is selected from the group consisting of H, C 1 -C 7 alkyl, C 3 -C 20 heterocyclyl and C 5 -C 20 aryl, each of which is optionally substituted; and
provided that Formula (I) excludes compounds wherein
Z is —N(R 1 )(OR 2 );
R 1 and R 2 are independently selected from the group consisting of H, C 1 -C 6 alkyl, aryl and heteroaryl;
L is a bond; and
is selected from the group consisting of hydrogen, aryl, aryl-alkyl-, heteroaryl, heteroaryl-alkyl-, heterocyclyl, cycloalkyl, heterocyclyl-alkyl, cycloalkyl-alkyl, C 1 -C 10 alkyl, (aryl) 2 -CH—C 0 -C 6 alkyl-, (aryl)(heteroaryl)CH—C 0 -C 6 alkyl- and (heteroaryl) 2 CH—C 0 -C 6 alkyl-, each of which is optionally substituted; and
Q comprises a ring selected from the group consisting of
wherein Y F is nitrogen or —CH<, and Z F is oxygen,
NH or —CH 2 — if Z F is not bonded to
or Z F is nitrogen or —CH< if Z F is bonded to
or
is selected from the group consisting of b-53, b-62 (wherein D 3 is
b-69 (wherein R 4 is H), b-70, b-72 (wherein D 3 is
b-92 and b-93; and
Q-J is selected from the group consisting of —X F —C 0-4 alkyl-aryl-C 0-4 alkyl-, —X F —C 0-4 alkyl-heteroaryl-C 0-4 alkyl-, and —X F —O 0-4 alkyl-heterocyclyl-C 0-4 alkyl-, wherein said alkyl, aryl, heteroaryl, and heterocyclyl are optionally substituted, and wherein said hetercyclyl is a mono- or bi-saturated or mono- or bi-unsaturated heterocyclic ring, and wherein
X F is selected from the group consisting of
wherein the left side attaches to
and wherein r and s are each independently 0, 1, 2, 3, 4 or 5, wherein r and s cannot be both 0 and when r or s are 0 then a direct bound in intended; each r′ is independently 0, 1, 3, 3 or 4 and r′ cannot be 0 when s is 0; R 4A is H, C 1-6 alkyl or phenyl; Y u is nitrogen or —CH<, and Z F is oxygen, NH or —CH 2 — if Z F is not bonded to
or Z F is nitrogen or —CH< if Z F is bonded to
and provided that Formula (I) excludes those compounds having the following structure:
wherein
X 9 is selected from the group consisting of CO, SO 2 and CH 2 ;
Y 9 is selected from the group consisting of N—R 9f , CH—OR 9f , CH—NR 9f R 9i and C═CH—CO—R 9g ;
A 9 and B 9 are independently selected from 5- or 6-membered rings;
R 9a , R 9b , R 9e and R 9d are independently selected from the group consisting of H, halogen, CF 3 , NO 2 , NR 9i R 9j , CN, COOH, (CH 2 ) 0-2 —CONR 9i R 9j , C 1-6 alkyl, OH, 0-C 1-6 alkyl, O-cyclopropyl, O—(CH 2 ) 2 —O—C 1-6 alkyl, O—(CH 2 ) 2 —NR 9i R 9j , O—CONHR 9i , CH 2 —Z 9 —R 9h , COR 9i , CR 9i R 9m R 9n , SR 9i , SO 2 R 9o , CR 9i NOR 9i , CR 9i NNR 9i R 9j j, a Q 9 -(CH 2 ) 2-9 CONHOH group, furan, thiophene, pyrrole, oxazole, thiazole, imidazole, pyrazole, isoxazole, isothiazole, 1,2,3-oxathiazole, 1,2,3-triazole, pyridine, pyridazine, pyrimidine, pyrazine, morpholine thiomorpholine, piperidine and pyrrolidine;
R 9e and R 9f are Q 9a -(CH 2 ) 2-9 CONHOH;
R 9g is NH—(CH 2 ) 2-9 CONHOH;
R 9h is a (CH 2 )P—R 9k group, wherein R 9k can be methyl or hydroxyl;
Z 9 is selected from the group consisting of O, NR 9L and S;
Q 9 is selected from the group consisting of a chemical bond, —O—, —S—, NR 9L —NR 9i CO—, —CONR 9i —, —W 9 —, —COW 9 —, wherein W 9 is piperidine or pyrrolidine;
Q 9a is a bond or a —CO—;
R 9i and R 9j are independently H or a C 1-6 alkyl;
R 9L is H or R 9h ;
R 9m and R 9n can either be a fluorine atom or oxygen atoms linked together by an alkyl chain consisting of 2 or 3 CH 2 ; and
R 9o is a C 1-6 alkyl; provided that (1) only one (CH 2 ) 2-9 CONHOH is present in the molecule and (2) when X 9 is CO and A 9 and B 9 are both benzene then R 9c and R 9d cannot signify Q 9 -(CH 2 ) 2-9 CONHOH.
2 . The compound according to claim 1 , wherein Q comprises a bridged heterocycle,
comprises a first ring structure, said first ring structure attached via a covalent bond to said bridged heterocycle and J comprises a second ring structure, said second ring structure attached via a covalent bond to said bridged heterocycle, each of which is optionally substituted.
3 . The compound according to claim 1 , wherein
is a radical selected from the group consisting of
4 . The compound according to claim 1 , wherein Q is an optionally substituted moiety selected from the group consisting of
or an (R,R) or (S,S) enantiomer or a mixture of enantiomers, or an (R,R) enantiomer, or an (S,S) enantiomer thereof, wherein G and G 1 are independently selected from —CH— and N; w1 and w2 are independently 0, 1, 2 or 3, provided that when both G and G 1 are N, then w1 and w2 are independently 1, 2 or 3; and wherein each ring structure includes a 0, 1, 2 or 3 carbon bridge between two non-adjacent carbon atoms, provided that
is absent when U 1 is H, N(R 3 )(R 3a )—C 2 -C 4 alkyl- or R 3 —O—C 2 -C 4 alkyl-.
5 . The compound according to claim 1 , wherein
Z is —N(R 1 )(OR 2 ); L is a covalent bond; J is selected from the group consisting of a covalent bond, ═CH—, —C 1 -C 8 alkyl-, —C 0 -C 3 alkyl-C 1 -C 8 heteroalkyl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-C 2 -C 8 alkenyl-C 0 -C 3 alkyl-, —C 0 -C 3 alkyl-C 2 -C 8 alkynyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 heteroalkyl-, —C 0 -C 6 alkyl-cycloalkyl-C 0 -C 6 alkyl-, —C 4 -C 6 heterocyclyl-aryl-C 0 -C 6 alkyl-, —C 4 -C 0 heterocyclyl-aryl-C 0 -C 6 heteroalkyl-, —C 0 -C 6 alkyl-C 4 -C 6 heterocyclyl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-heteroaryl-C 0 -C 6 heteroalkyl-, —C 4 -C 0 heterocyclyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 alkynyl-, —C 0 -C 6 alkyl-heteroaryl-C 2 -C 6 alkynyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 alkynyl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-heteroaryl-C 2 -C 6 alkenyl-, —C 2 -C 6 alkenyl-aryl-C 0 -C 6 alkyl-, —C 2 -C 6 alkenyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkylaryl-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkylaryl-heteroaryl-C 0 -C 6 alkyl- and —C 0 -C 6 alkyl-C 3 -C 6 cycloalkyl-C 0 -C 6 alkyl-, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl moiety is optionally substituted, wherein when J is ═CH—, Q is a covalent bond and B is attached through a carbon sp 2 to J; Q is a moiety selected from the group consisting of
or an optionally substituted (R,R) or (S,S) enantiomer or a mixture of enantiomers, wherein n is 0, 1, 2 or 3; and
U is selected from the group consisting of —C 0 -C 8 alkyl-C(O)—C 0 -C 3 alkyl-, —C 1 -C 8 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-O—C(O)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—C(S)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-O—C(S)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—S(O) 2 —C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-heterocyclyl-C 0 -C 3 alkyl-, a covalent bond and —O—C 2 -C 4 alkyl-; and
U 1 is selected from the group consisting of H, —C 0 -C 8 alkyl-C(O)—C 0 -C 3 alkyl-, —C 1 -C 8 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-O—C(O)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—C(S)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-O—C(S)—C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-N(R 3 )—S(O) 2 —C 0 -C 3 alkyl-, —C 0 -C 8 alkyl-heterocyclyl-C 0 -C 3 alkyl-, a covalent bond, (R 3 )(R 3a )N—C 2 -C 4 alkyl-, —O—C 2 -C 4 alkyl-, and R 3 —O—C 2 -C 4 alkyl-;
wherein
is absent when Q is structure (a-1), (a-2), (a-3) or when U 1 is H, N(R 3 )(R 3a )—C 2 -C 4 alkyl- or R 3 —O—C 2 -C 4 alkyl-.
6 . The compound according to claim 5 , wherein J is selected from the group consisting of a —C 0 -C 3 alkyl-C 1 -C 8 heteroalkyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 heteroalkyl-, —C 0 -C 6 alkyl-cycloalkyl-C 0 -C 6 alkyl-, —C 4 -C 6 heterocyclyl-aryl-C 0 -C 6 alkyl-, —C 4 -C 6 heterocyclyl-aryl-C 0 -C 6 heteroalkyl-, —C 0 -C 6 alkyl-C 4 -C 6 heterocyclyl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-heteroaryl-C 0 -C 6 heteroalkyl-, —C 4 -C 0 heterocyclyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 alkynyl-, —C 0 -C 6 alkyl-heteroaryl-C 2 -C 6 alkynyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 alkynyl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-aryl-C 2 -C 6 alkenyl-, —C 0 -C 6 alkyl-heteroaryl-C 2 -C 6 alkenyl-, —C 2 -C 6 alkenyl-aryl-C 0 -C 6 alkyl-, —C 2 -C 0 alkenyl-heteroaryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkylaryl-aryl-C 0 -C 6 alkyl-, —C 0 -C 6 alkylaryl-heteroaryl-C 0 -C 6 alkyl- and —C 0 -C 6 alkyl-C 3 -C 6 cycloalkyl-C 0 -C 6 alkyl-, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, aryl, heteroaryl, heterocyclyl, and cycloalkyl moiety is optionally substituted.
7 . The compound according to claim 1 , wherein
J is selected from the group consisting of —C 1 -C 8 alkyl-, —C 0 -C 6 alkyl-aryl-C 0 -C 3 alkyl-C 2 alkenyl-C 0 -C 3 alkyl, —C 0 -C 6 alkyl-heteroaryl-C 0 -C 3 alkyl-C 2 alkenyl-C 0 -C 3 alkyl, —C 0 -C 6 alkyl-aryl-C 0 -C 6 alkyl- and —C 0 -C 6 alkyl-heteroaryl-C 0 -C 6 alkyl-, wherein each is optionally substituted; Q is selected from the group consisting of a covalent bond, —C 1 -C 8 alkyl-, ═N—O—, —C 0 -C 6 alkyl-N(R 3 )—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-heterocyclyl-C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-C(O)—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-O—C 0 -C 3 alkyl-, —C 0 -C 6 alkyl-(CR 3 ═CR 3 ) 1-2 —C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-(C≡C) 1-2 —C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-N(R 3 )—C(O)—C 0 -C 3 alkyl-, wherein each alkyl and heterocyclyl moiety is optionally substituted; or Q is selected from the group consisting of:
wherein
U 1 is selected from the group consisting of —C 0 -C 8 alkyl-C(O)—C 0 -C 3 alkyl-, —C 1 -C 8 alkyl-, —C 0 -C 8 alkyl-O—C(O)—C 0 -C 3 alkyl- and a covalent bond;
wherein, when B is attached to Q via a N in B, then Q is selected from the group consisting of a covalent bond, —C(O)—C 1 -C 3 alkyl-O—, —C 1 -C 8 alkyl-, —C 0 -C 6 alkyl-C(O)—C 0 -C 3 alkyl-, —C 2 -C 6 alkyl-O—C 0 -C 3 alkyl-, —C 1 -C 6 alkyl-(CR 3 ═CR 3 ) 1-2 —C 0 -C 6 alkyl- and —C 1 -C 6 alkyl-(C≡C) 1-2 —C 0 -C 6 alkyl-, wherein each alkyl moiety is optionally substituted;
provided that
is absent when Q is
and
is selected from the group consisting of hydrogen, aryl, cycloalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, aryl-alkyl-, (heteroaryl) 2 -CH—C 0 -C 6 alkyl- and (aryk) 2 -CH—C 0 -C 6 alkyl-, each of which is optionally substituted, provided that Q is
or
is a radical selected from the group consisting of
8 . The compound according to claim 1 , represented by the Formula (II):
and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein
Z is selected from the group consisting of —N(R 1 )OR 2 and H;
L is selected from the group consisting of a covalent bond and —N(OR 2 )—;
wherein, when L is —N(OR 2 )—, then Z is H; and
wherein, when Z is H, then L is —N(OR 2 )—;
R 1 and R 2 are independently selected from the group consisting of —H and C 1 -C 6 alkyl;
W is nitrogen or carbon;
D 1a -D 2a is selected from the group consisting of
wherein, * represents the point of attachment to Q;
D 3 is independently selected from the group consisting of —C(R 55 )(R 66 ), —C(R 55 )(OH)—, —C(O)—, —O—, —N(R 77 )— and —S(O) 0-2 —;
are independently selected from the group consisting of phenyl, heteroaryl and heterocyclyl, wherein each phenyl, heteroaryl and heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, —CF 3 , —OCF 3 , —NO 2 , —CN, —C 1 -C 6 alkyl, —C 1 -C 6 alkoxyl, —O—C 2 -C 6 alkyl-O-R 53 , —O—R 53 , —C 0 -C 6 alkyl-S(O) 0-2 —R 53 , —C 0 -C 6 alkyl-C(O)—R 53 , —C 0 -C 6 alkyl-C(O)NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 C(O)—R 53 , —C 0 -C 6 alkyl-S(O) 2 NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 S(O) 2 —R 53 , —C 0 -C 6 alkyl-OC(O)NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 C(O)O—R 53 , —C 0 -C 6 alkyl-NR 52 C(O)NR 50 R 51 , —C 0 -C 6 alkyl-C(O)O—R 53 , —C 0 -C 6 alkyl-OC(O)—R 53 , —C 0 -C 6 alkyl-aryl, —C 0 -C 6 alkyl-heteroaryl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, —C 0 -C 6 alkyl-heterocyclyl, —C 0 -C 6 alkyl-NR 50 R 51 , —O—C 2 -C 6 alkyl-NR 50 R 51 , —NR 53 —C 2 -C 6 alkyl-NR 50 R 51 and —O-heterocyclyl-R 53 ;
R 44 is independently selected from the group consisting of —H, —C 1 -C 6 alkyl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl and —C 0 -C 4 alkyl-heterocyclyl;
R 50 and R 51 are independently selected from the group consisting of H, —C 1 -C 6 alkyl, —C 2 -C 6 alkyl-O—C 1 -C 6 alkyl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
or
R 50 and R 51 , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein the heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
R 52 is independently selected from the group consisting of —H, —C 1 -C 6 alkyl, —C 2 -C 6 alkyl-O—C 1 -C 6 alkyl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
R 53 is independently selected from the group consisting of —C 1 -C 6 alkyl, —C 0 -C 4 alkyl-C 3 -C 7 cycloalkyl, —C 0 -C 4 alkyl-aryl, —C 0 -C 4 alkyl-heteroaryl and —C 0 -C 4 alkyl-heterocyclyl, wherein each alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
R 55 and R 66 are independently selected from the group consisting of —H, —C 1 -C 6 alkyl, —C 1 -C 6 alkoxyl, —C 0 -C 4 alkyl-C 3 -C 7 cycloalkyl and —C 0 -C 4 alkyl-heterocyclyl;
or
R 55 and R 66 , together with the atom to which they are attached, optionally form a 3-7 membered cycloalkyl or heterocyclic ring, wherein each cycloalkyl and heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
R 77 is independently selected from the group consisting of —H, —C 1 -C 6 alkyl, —C 1 -C 6 heteroalkyl, —C 3 -C 7 cycloalkyl, —C(O)—R 53 , —C(O)O—R 53 , -cycloalkyl, —C 1 -C 4 alkyl-cycloalkyl, phenyl, —C 1 -C 4 alkyl-phenyl, -heterocyclyl, —C 1 -C 4 alkyl-heterocyclyl and —C 2 -C 6 alkyl-NR 88 R 99 , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, —OH and oxo, wherein each phenyl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, —CN, —C 1 -C 4 alkyl, —C 1 -C 4 alkoxyl, —O—C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —CF 3 , —OCF 3 , —NO 2 , —C 1 -C 6 alkyl-S(O) 0-2 R 53 , —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 and —N(C 1 -C 6 alkyl) 2 ;
or R 77 together with the N to which it is attached may form a ring with
wherein the ring is a 5-7 membered heterocyclic ring, and
R 88 and R 99 are independently selected from the group consisting of —H, —C 1 -C 6 alkyl, —C 2 -C 6 alkyl-O—C 1 -C 6 alkyl and —C 0 -C 4 alkyl-C 3 -C 7 cycloalkyl, wherein each cycloalkyl and alkyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 6 alkyl-aryl;
or
R 88 and R 99 , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein an heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, —OH, amino or —CN
9 . The compound according to claim 8 , represented by the Formula (III):
wherein
R 140 is selected from the group consisting of H, —OH, halo, —CN, —C 1 -C 4 alkyl, —C 1 -C 4 alkoxyl, —O—C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —CF 3 , —OCF 3 , —NO 2 , —C 1 -C 6 alkyl-S(O) 0-2 R 53 , —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 and —N(C 1 -C 6 alkyl) 2 .
10 . The compound according to claim 1 , represented by the Formula (IV):
wherein
R 140 is selected from the group consisting of H, —OH, halo, —CN, —C 1 -C 4 alkyl, —C 1 -C 4 alkoxyl, —O—C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —CF 3 , —OCF 3 , —NO 2 , —C 1 -C 6 alkyl-S(O) 0-2 R 53 , —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 and —N(C 1 -C 6 alkyl) 2 ;
xa and xb denote numbers that are each independently selected from 0, 1 and 2; and
R 150 and R 160 are independently selected from the group consisting of H, halo, —CN, —CF 3 , —OCF 3 , —C 1 -C 6 alkyl, —C 1 -C 6 alkoxyl, —O—C 2 -C 6 alkyl-O—R 53 , —OR 53 , —C 0 -C 6 alkyl-S(O) 0-2 —R 53 , —C 0 -C 6 alkyl-C(O)—R 53 , —C 0 -C 6 alkyl-C(O)NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 C(O)—R 53 , —C 0 -C 6 alkyl-S(O) 2 NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 S(O) 2 —R 53 , —C 0 -C 6 alkyl-OC(O)NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 C(O)O—R 53 , —C 0 -C 6 alkyl-NR 52 C(O)NR 50 R 51 , —C 0 -C 6 alkyl-C(O)O—R 53 , —C 0 -C 6 alkyl-OC(O)—R 53 , —C 0 -C 6 alkyl-aryl, —C 0 -C 6 alkyl-heteroaryl, —C 0 -C 6 alkyl-cycloalkyl, —C 0 -C 6 alkyl-heterocyclyl, —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 , —O—C 2 -C 6 alkyl-NR 50 R 51 , —NR 53 —C 2 -C 6 alkyl-NR 50 R 51 and —O-heterocyclyl-R 53 , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, —OH and oxo, and wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, —CN, —C 1 -C 4 alkyl, —C 1 -C 4 alkoxyl, —O—C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —CF 3 , —OCF 3 , —NO 2 , —C 1 -C 6 alkyl-S(O) 0-2 R 53 , —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 and —N(C 1 -C 6 alkyl) 2 ;
R 50 and R 51 are independently selected from the group consisting of H, —C 1 -C 6 alkyl, —C 2 -C 0 alkyl-O—C 1 -C 6 alkyl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
or
R 50 and R 51 , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein the heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
R 52 is independently selected from the group consisting of —H, —C 1 -C 6 alkyl, —C 2 -C 6 alkyl-O—C 1 -C 6 alkyl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
R 53 is independently selected from the group consisting of —C 1 -C 6 alkyl, —C 0 -C 4 alkyl-C 3 -C 7 cycloalkyl, —C 0 -C 4 alkyl-aryl, —C 0 -C 4 alkyl-heteroaryl and —C 0 -C 4 alkyl-heterocyclyl, wherein each alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl.
11 . The compound according to claim 1 , represented by the Formula (V):
wherein
R 140 is selected from the group consisting of H, —OH, halo, —CN, —C 1 -C 4 alkyl, —C 1 -C 4 alkoxyl, —O—C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —CF 3 , —OCF 3 , —NO 2 , —C 1 -C 6 alkyl-S(O) 0-2 R 53 , —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 and —N(C 1 -C 6 alkyl) 2 ;
xb denotes a number selected from 0, 1 and 2; and
R 150 and R 160 are independently selected from the group consisting of H, halo, —CN, —CF 3 , —OCF 3 , —C 1 -C 6 alkyl, —C 1 -C 6 alkoxyl, —O—C 2 -C 6 alkyl-O—R 53 , —OR 53 , —C 0 -C 6 alkyl-S(O) 0-2 —R 53 , —C 0 -C 6 alkyl-C(O)—R 53 , —C 0 -C 6 alkyl-C(O)NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 C(O)—R 53 , —C 0 -C 6 alkyl-S(O) 2 NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 S(O) 2 —R 53 , —C 0 -C 6 alkyl-OC(O)NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 C(O)O—R 53 , —C 0 -C 6 alkyl-NR 52 C(O)NR 50 R 51 , —C 0 -C 6 alkyl-C(O)O—R 53 , —C 0 -C 6 alkyl-OC(O)—R 53 , —C 0 -C 6 alkyl-aryl, —C 0 -C 6 alkyl-heteroaryl, —C 0 -C 6 alkyl-cycloalkyl, —C 0 -C 6 alkyl-heterocyclyl, —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 , —O—C 2 -C 6 alkyl-NR 50 R 51 , —NR 53 —C 2 -C 6 alkyl-NR 50 R 51 and —O-heterocyclyl-R 53 , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, —OH and oxo, and wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, —CN, —C 1 -C 4 alkyl, —C 1 -C 4 alkoxyl, —O—C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —CF 3 , —OCF 3 , —NO 2 , —C 1 -C 6 alkyl-S(O) 0-2 R 53 , —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 and —N(C 1 -C 6 alkyl) 2 ;
xc is 0 or 1; and
R 170 is selected from the group consisting of H, halo, —CN, —CF 3 , —OCF 3 , —C 1 -C 6 alkyl, —C 1 -C 6 alkoxyl, —O—C 2 -C 6 alkyl-O—R 53 , —OR 53 , —C 0 -C 6 alkyl-S(O) 0-2 —R 53 , —C 0 -C 6 alkyl-C(O)—R 53 , —C 0 -C 6 alkyl-C(O)NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 C(O)—R 53 , —C 0 -C 6 alkyl-S(O) 2 NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 S(O) 2 —R 53 , —C 0 -C 6 alkyl-OC(O)NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 C(O)O—R 53 , —C 0 -C 6 alkyl-NR 52 C(O)NR 50 R 51 , —C 0 -C 6 alkyl-C(O)O—R 53 , —C 0 -C 6 alkyl-OC(O)—R 53 , —C 0 -C 6 alkyl-aryl, —C 0 -C 6 alkyl-heteroaryl, —C 0 -C 6 alkyl-cycloalkyl, —C 0 -C 6 alkyl-heterocyclyl, —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 , —O—C 2 -C 6 alkyl-NR 50 R 51 , —NR 53 —C 2 -C 6 alkyl-NR 50 R 51 and —O-heterocyclyl-R 53 , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, —OH and oxo, wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, —CN, —C 1 -C 4 alkyl, —C 1 -C 4 alkoxyl, —O—C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —CF 3 , —OCF 3 , —NO 2 , —C 1 -C 6 alkyl-S(O) 0-2 R 53 , —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 and —N(C 1 -C 6 alkyl) 2
R 50 and R 51 are independently selected from the group consisting of H, —C 1 -C 6 alkyl, —C 2 -C 6 alkyl-O—C 1 -C 6 alkyl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
or
R 50 and R 51 , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein the heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
R 52 is independently selected from the group consisting of —H, —C 1 -C 6 alkyl, —C 2 -C 6 alkyl-O—C 1 -C 6 alkyl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
R 53 is independently selected from the group consisting of —C 1 -C 6 alkyl, —C 0 -C 4 alkyl-C 3 -C 7 cycloalkyl, —C 0 -C 4 alkyl-aryl, —C 0 -C 4 alkyl-heteroaryl and —C 0 -C 4 alkyl-heterocyclyl, wherein each alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
12 . The compound according to claim 11 , represented by the Formula (VI):
13 . The compound according to claim 1 , represented by the Formula (VII):
wherein
R 140 is selected from the group consisting of H, —OH, halo, —CN, —C 1 -C 4 alkyl, —C 1 -C 4 alkoxyl, —O—C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —CF 3 , —OCF 3 , —NO 2 , —C 1 -C 6 alkyl-S(O) 0-2 R 53 , —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 and —N(C 1 -C 6 alkyl) 2 ;
xa and xb denote numbers that are each independently selected from 0, 1 and 2; and
R 150 and R 160 are independently selected from the group consisting of H, halo, —CN, —CF 3 , —OCF 3 , —C 1 -C 6 alkyl, —C 1 -C 6 alkoxyl, —O—C 2 -C 6 alkyl-O—R 53 , —OR 53 , —C 0 -C 6 alkyl-S(O) 0-2 —R 53 , —C 0 -C 6 alkyl-C(O)—R 53 , —C 0 -C 6 alkyl-C(O)NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 C(O)—R 53 , —C 0 -C 6 alkyl-S(O) 2 NR 50 R 51 , —C 0 -C 6 alkyl-NR 52 S(O) 2 —R 53 , —C 0 -C 6 alkyl-OC(O)NR 50 R 51 , —C 0 -C 0 alkyl-NR 52 C(O)O—R 53 , —C 0 -C 6 alkyl-NR 52 C(O)NR 50 R 51 , —C 0 -C 6 alkyl-C(O)O—R 53 , —C 0 -C 6 alkyl-OC(O)—R 53 , —C 0 -C 6 alkyl-aryl, —C 0 -C 6 alkyl-heteroaryl, —C 0 -C 6 alkyl-cycloalkyl, —C 0 -C 6 alkyl-heterocyclyl, —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 , —O—C 2 -C 6 alkyl-NR 50 R 51 , —NR 53 —C 2 -C 6 alkyl-NR 50 R 51 and —O-heterocyclyl-R 53 , wherein each alkyl and heteroalkyl is optionally substituted with one or three substituents independently selected from the group consisting of F, —OH and oxo, and wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one or two substituents independently selected from the group consisting of halo, —CN, —C 1 -C 4 alkyl, —C 1 -C 4 alkoxyl, —O—C 2 -C 4 alkyl-O—C 1 -C 4 alkyl, —CF 3 , —OCF 3 , —NO 2 , —C 1 -C 6 alkyl-S(O) 0-2 R 53 , —NH 2 , —NR 50 R 51 , —C 1 -C 6 alkyl-NR 50 R 51 and —N(C 1 -C 6 alkyl) 2 ;
R 50 and R 51 are independently selected from the group consisting of H, —C 1 -C 6 alkyl, —C 2 -C 0 alkyl-O—C 1 -C 6 alkyl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
or
R 50 and R 51 , together with the N atom to which they are attached, optionally form a 3-10 membered heterocyclic ring, wherein the heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl;
R 52 is independently selected from the group consisting of —H, —C 1 -C 6 alkyl, —C 2 -C 6 alkyl-O—C 1 -C 6 alkyl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl; and
R 53 is independently selected from the group consisting of —C 1 -C 6 alkyl, —C 0 -C 4 alkyl-C 3 -C 7 cycloalkyl, —C 0 -C 4 alkyl-aryl, —C 0 -C 4 alkyl-heteroaryl and —C 0 -C 4 alkyl-heterocyclyl, wherein each alkyl, aryl, heteroaryl and heterocyclyl is optionally substituted with one or three substituents independently selected from the group consisting of halo, —OH, amino, —CN or —C 1 -C 4 alkyl.
14 . The compound according to claim 1 , represented by the Formula VIII:
and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein
R 4 is independently selected from the group consisting of —H, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkyl-R 3 , —C 0 -C 6 alkyl-OR 3 , —C 0 -C 6 alkyl-OR 1 , —C 0 -C 6 alkyl-C(O)—OR 3 , —C 0 -C 6 alkyl-C(O)NR 3 R 3a , —CH═CH—C(O)—OR 3 , —CH═CH—C(O)—N(R 3 )(R 3a ), —N(R 3 )—C(O)—CF 3 , —N(R 3 )—C 2 -C 6 alkyl-N(R 3 )(R 3a ), —C 0 -C 6 alkyl-N(R 3 )(R 3a ), —N(R 3 )—C(O)—C 1 -C 6 alkyl-R 3 , —N(R 3 )—S(O) 2 —C 1 -C 6 alkyl-R 3 , —S(O) 2 —N(R 3 )R 3a , —O—C 2 -C 6 alkyl-N(R 3 )(R 3a ), —O—C 2 -C 6 alkyl-OR 1 , —S—R 3 , —S(O)—C 1 -C 6 alkyl-R 3 , —S(O) 2 —C 1 -C 6 alkyl-R 3 , C 3 -C 6 cycloalkyl, heterocyclyl, C 4 -C 7 heterocyclyl-R 3 , —O—C 2 -C 4 alkyl-heterocyclyl, —O-heterocyclyl-C(O)—OR 3 , —O—C 0 -C 4 alkyl-aryl, —O—C 0 -C 4 alkyl-heteroaryl, —O—C(O)—NR 3 —C 0 -C 4 alkyl-aryl, —O—C(O)—NR 3 —C 0 -C 4 alkyl-heteroaryl, —O—C 0 -C 4 alkyl-heterocyclylaryl, —O—C 0 -C 4 alkyl-heterocyclyl-heteroaryl, —N(R 3 )—C 2 -C 4 alkyl-heterocyclyl, —N(R 3 )C(O)N(R 3 )—C 0 -C 4 alkyl-heterocyclyl-R 3 , —C 0 -C 4 alkyl-OC(O)—R 3 , —C 0 -C 4 alkyl-N(R 3 )C(O)—O—R 3 , —C 0 -C 4 alkyl-heterocyclyl-C(O)—O—R 3 , —N(R 3 )—C 2 -C 4 alkyl-heterocyclyl, F, Cl, Br, I, NO 2 , —CF 3 , —OCF 3 , —OCHF 2 , —SCF 3 , —SF 5 , —SO 3 H, —CN, —C 1 -C 6 alkylaryl, aryl, heteroaryl, cycloalkyl, —C 1 -C 6 alkylheteroaryl, wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moeity of the aformentioned R 4 is optionally substituted;
each A is independently selected from the group consisting of N, —N-oxide, —CH═ and —C(R 4 )═, wherein no more than two A per 5 or 6 membered ring are N, and wherein no more than one A is —N-oxide;
Z is —N(R 1 )OR 2 or H;
L is a covalent bond or —C 0 -C 3 alkyl-N(OR 2 )—;
wherein, when L is C 0 -C 3 alkyl-N(OR 2 )—, then Z is H; and
wherein, when Z is H, then L is —C 0 -C 3 alkyl-N(OR 2 )—;
G 2 is carbon or N;
U 2 is selected from the group consisting of a covalent bond, —C 1 -C 8 alkyl-, —C(R 300 )(R 400 )—C(O)—C(R 301 )(R 401 ) C 0 -C 2 alkyl-C(O)—O—C 0 -C 4 alkyl-, —C 0 -C 2 alkyl-C(O)—C 0 -C 4 alkyl-, —C 0 -C 2 alkyl-C(O)—NR 3 —C 0 -C 4 alkyl-, —C(O)—O—C(R 301 )(R 401 )—, C(O)C(R 301 )(R 401 )— and —C(O)—NR 3 —C(R 300 )(R 400 )—,
each R 3 is independently selected from the group consisting of —H, alkyl, C 0 -C 3 alkyl-heterocyclyl, C 1 -C 3 alkyl-C 2 -C 6 alkenyl, C 1 -C 3 alkyl-C 2 -C 3 alkynyl, —C 2 -C 4 alkyl-OR 1 , —C 2 -C 4 alkyl-NR 3b R 3c , —C 2 -C 4 alkyl-NR 1 R 2 , heteroalkyl, C 0 -C 6 alkylheteroaryl, C(O)CF 3 , —C(O)—NH 2 , —C(O)—NR 3b R 3c , —C(O)—NR 1 R 2 , —C(O)—OR 1 , —S(O) 2 —NR 1 R 2 , —S(O) 2 —R 1 , —C(O)—R 1 , —C 3 -C 6 cycloalkyl, —C 0 -C 3 alkyl-C 3 -C 7 cycloalkyl, —C 1 -C 6 alkylaryl, aryl, C 0 -C 3 alkyl-heteroaryl and heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted with from one to three independently selected substituents;
each R 3a is independently selected from the group consisting of —H, alkyl, heterocyclyl, C 2 -C 6 alkenyl, C 2 -C 3 alkynyl, C 2 -C 4 alkyl-OR 1 , heteroalkyl, heteroaryl, C 0 -C 6 alkylheteroaryl, C(O)CF 3 , —C(O)—NH 2 , —C 3 -C 6 cycloalkyl, -alkyl-C 3 -C 6 cycloalkyl, —C 1 -C 6 alkylaryl, aryl, alkylheteroaryl and heteroaryl, covalent bond, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl and heteroaryl moiety is optionally substituted;
wherein R 3 and R 3a , together with the atom to which they are attached, optionally form a heterocyclic ring, wherein the heterocyclyl moiety is optionally substituted;
R 300 and R 400 are independently selected from the group consisting of —H, —F, —C 1 -C 6 alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl;
R 301 and R 401 are independently selected from the group consisting of —H, F, OR 1 , —NR 3 R 3a —, —C 1 -C 6 alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl;
R 200 , R 201 , R 202 and R 203 are independently selected from the group consisting of —H, —C 1 -C 6 alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl; and
is selected from the group consisting of hydrogen, aryl, heteroaryl, alkyl, heterocyclyl, cycloalkyl, wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, —CF 3 , —OCF 3 , —SCF 3 , —SF 5 , —NO 2 , —CN, —C 1 -C 6 alkyl, —C 1 -C 6 alkoxyl, —O—C 2 -C 6 alkyl-O—R 1 , —O—R 1 , —OCF 2 H, —C 0 -C 6 alkyl-S(O) 0-2 —R 1 , —C 0 -C 6 alkyl-C(O)—R 1 , —C 0 -C 6 alkyl-C(O)NR 3 R 3a , —C 0 -C 6 alkyl-NR 3 C(O)—R 2 , —C 0 -C 6 alkyl-S(O) 2 NR 3 R 3a , —C 0 -C 6 alkyl-NR 3 S(O) 2 —R 2 , —C 0 -C 6 alkyl-OC(O)NR 3 R 3a , —C 0 -C 6 alkyl-NR 3 C(O)O—R 1 , —C 0 -C 6 alkyl-NR 1 C(O)NR 3 R 3a , —C 0 -C 6 alkyl-C(O)O—R 1 , —C 0 -C 6 alkyl-OC(O)—R 1 , —C 0 -C 6 alkyl-aryl, —C 0 -C 6 alkyl-heteroaryl, —C 0 -C 6 alkyl-C 3 -C 7 cycloalkyl, —C 0 -C 6 alkyl-heterocyclyl, —C 0 -C 6 alkyl-NR 3 R 3a and —O—C 2 -C 6 alkyl-NR 3 R 3a ; and
R 1 and R 2 are independently selected from the group consisting of —H, C 1 -C 6 alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protecting group.
15 . The compound according to claim 14 , wherein the moiety
is a radical selected from the group consisting of
16 . The compound according to claim 14 , represented by the Formula (IX):
or a (R,R) or (S,S) enantiomer, scalemic or a mixture of enantiomers thereof.
17 . The compound according to claim 14 , represented by the Formula (X):
or a (R,R) or (S,S) enantiomer, scalemic or a mixture of enantiomers thereof.
18 . The compound according to claim 14 , wherein the moiety
is a radical selected from the group consisting of
19 . The compound according to claim 1 , represented by the Formula (XI):
and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof,
wherein
is
and
Q 1 is selected from the group consisting of —C 1 -C 6 alkyl, covalent bond, —C 0 -C 6 alkyl-O—C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-NR 3 —C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-S(O) 0-2 —C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-NR 3 C(O)—C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-C(O)NR 3 —C 0 -C 6 alkyl- and —C 0 -C 6 alkyl-OC(O)NR 3 —C 0 -C 6 alkyl-.
20 . The compound according to claim 1 , represented by the Formula (XII):
and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof,
wherein
is
and
Q 2 is selected from the group consisting of —C 1 -C 6 alkyl, covalent bond, —C 0 -C 6 alkyl-O—C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-NR 3 —C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-S(O) 0-2 —C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-NR 3 C(O)—C 0 -C 6 alkyl-, —C 0 -C 6 alkyl-C(O)NR 3 —C 0 -C 6 alkyl- and —C 0 -C 6 alkyl-OC(O)NR 3 —C 0 -C 6 alkyl-.
21 . The compound according to claim 1 , represented by the Formula (XIII):
and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof,
wherein
is a radical selected from the group consisting of
22 . The compound according to claim 1 , represent by the Formula (XIV):
and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs, polymorphs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof,
wherein
is a radical selected from the group consisting of aryl, heteroaryl, heterocyclyl, cycloalkyl,
wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted.
23 . A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
24 . A method of inhibiting histone deacetylase, the method comprising contacting the histone deacetylase with a compound according to claim 1 or a composition thereof.
25 . A method of treating a polyglutamine (polyQ) expansion disease, comprising administering to an individual in need of treatment a therapeutically effective amount of a compound according to claim 1 , or a composition thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.